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Mo le ku lar ni me ha niz mi in zu lin ske re zis ten ci je, pre ti los ti i me ta bo lič kog sin dro ma
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Sa že tak
In zu lin ska re zis ten ci ja je sta nje po re me će ne spo sob nos ti od go vo ra na dje lo-
va nje in zu li na. Naj češ ći os nov ni uz rok je sre diš nja pre ti lo st, ia ko je pri mar na 
in zu lin ska re zis ten ci ja mo gu ća i u oso ba s nor mal nom te ži nom. Su viš no ab do-
mi nal no mas no tki vo ot puš ta po ve ća ne ko li či ne fak to ra tu mor ske nek ro ze α i 
slo bod nih mas nih ki se li na, što iz rav no ut je če na in zu lin sko sig na li zi ra nje, sma-
nju je preu zi ma nje glu ko ze u mi ši ći ma, do vo di do pret je ra ne sin te ze trig li ce ri-
da i iza zi va glu ko neo ge ne zu u jet ri. Osta li čim be ni ci za ko je se pret pos tav lja 
da ig ra ju ulo gu u in zu lin skoj re zis ten ci ji su adi po nek tin (sni že nje), lep tin, IL-6 
i ne ki dru gi adi po ki ni. Smat ra se da je obič na pre ti lo st po li ge nog pod ri jet la 
uz ut je caj "pre ti lo ge ne" oko li ne – po ve ćan unos hra ne i ne dos ta tak tje les ne 
ak tiv nos ti. Da naš nja vi so ka učes ta lo st pre ti los ti mog la bi se ob jas ni ti evo lu cij-
skim pri tis kom za oda bir ge na ko ji pro mi ču poh ra nu mas ti za pre živ lje nje u 
vri je me gla do va nja. In zu lin ska re zis ten ci ja je pri sut na za jed no sa sre diš njom 
pre ti los ti, hi per ten zi jom i dis li pi de mi jom, ko je se skup no oz na ča va ju kao me-
ta bo lički sin drom. Ove po jav nos ti pred stav lja ju sna žne čim be ni ke ri zi ka za še-
ćer nu bo le st tipa 2 i kar dio vas ku lar nu bo le st.
Ključ ne ri je či:  in zu lin ska re zis ten ci ja, pre ti lo st, me ta bo li čki sin drom, adi po-
ki ni
Abstract
Insulin resistance is a state of impaired responsiveness to insulin action. The 
most common underlying cause is central obesity although primary insulin 
resistance in normal-weight individuals is also possible. Excess abdominal 
adipose tissue has been shown to release increased amounts of tumor necro-
sis factor α and free fatty acids, which directly aff ect insulin signaling, dimi-
nish glucose uptake in the muscle, drive exaggerated triglyceride synthesis 
and induce gluconeogenesis in the liver. Other factors presumed to play a role 
in insulin resistance are adiponectin (a decrease), leptin, IL-6 and some other 
adipokines. Common obesity is thought to be of polygenic origin with infl u-
ence of "obesogenic" environment, i.e. increased food intake and the lack of 
physical activity. Today's high prevalence of obesity could be explained by 
evolutionary pressure for selection of genes promoting fat storage to survi-
ve in starvation. Insulin resistance frequently coexists with central obesity, 
hypertension and dyslipidemia, which have collectively been denoted as me-
tabolic syndrome. These manifestations represent strong risk factors for dia-
betes mellitus type 2 and cardiovascular disease.
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Uvod
In zu lin ska re zis ten ci ja (IR) de fi  ni ra se kao od go vor na in zu-
lin ma nji od nor mal nog, što do vo di do hi pe rin zu li ne mi je 
ka ko bi se od r ža li eug li ke mij ski uv je ti (1). Sto ga kom pen-
za cij ska hi pe rin zu li ne mi ja zbog po ja ča nog lu če nja β-sta-
ni ca ob ve zat no pop rat no obi ljež je uz IR. Glav ne zna čaj ke 
IR su lo še in hi bi ra na glu ko neo ge ne za, po re me će no preu-
zi ma nje glu ko ze u mi ši ći ma i lo še in hi bi ra na li po li za u 
mas nom tki vu. Kli nič ki bi lje zi IR su vis ce ral na pre ti lo st, crn -
ka s ta akan to za (2), ak ne, pre kom jer na dla ka vo st (3),  jet re-
na stea to za (1).
Zlat ni stan da rd za proc je nu IR je hi pe rin zu li ne mij ska eug-
li ke mij ska spo na (en gl. cla mp): in zu lin se da je po us ta lje-
Introduction
Insulin resistance (IR) is defi ned as less than normal re-
sponse to insulin, which leads to hyperinsulinemia for 
euglycemic conditions to be maintained (1). Compensa-
tory hyperinsulinemia due to enhanced β-cell secretion 
is therefore an obligate accompanying feature in IR. The 
main characteristics of IR are disinhibited gluconeogen-
esis, impaired uptake of glucose by muscle and disinhib-
ited lipolysis in adipose tissue.
Clinical markers of IR are visceral obesity, acanthosis nigri-
cans (2), acne, hirsutism (3) and hepatic steatosis (1).
The golden standard for evaluation of IR is hyperinsu-
linemic euglycemic clamp: insulin is infused at a con-
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noj sto pi in fu zi jom, a glu ko za se od r ža va na ba zal nim 
ra zi na ma in fu zi jom glu ko ze. Sto pa in fu zi je glu ko ze da je 
mje ru preu zi ma nja glu ko ze u svim tki vi ma (4). Al ter na tiv-
ne mje re za IR su kon cen tra ci je in zu li na u plaz mi na taš te 
(2) i proc je na mo de la ho meos ta ze (en gl. homeos ta sis mo-
del as ses sme nt, HOMA) iz ve de na iz kon cen tra ci ja in zu li na 
i glu ko ze u plaz mi na taš te (5).
Etio lo gi ja IR uk lju ču je ge net ske čim be ni ke ko ji re zul ti ra-
ju sin drom nim ob li ci ma IR, te čim be ni ke oko li ne: unos 
hra ne, ne dos tat na tje les na ak tiv no st, sta re nje, pu še nje ili 
uzi ma nje li je ko va – tia zid nih diu re ti ka, be ta ad re ner gič nih 
an ta go nis ta, glu ko kor to koi da, ko ji mo gu uz ro ko va ti IR ili 
dop ri ni je ti nje go vu nas tan ku (2). Naj važ ni ji čim be nik je pre-
ti lo st ko ja je obič no slo že nog po li ge net skog i oko lin skog 
pod ri jet la (2, 6). Ab do mi nal no mas no tki vo je iz vor slo bod-
nih mas nih ki se li na (en gl. free fat ty aci ds, FFA) i raz li či tih 
hor mo na (adi po ki na) ko ji su up le te ni u raz voj IR. Na sup rot 
to me, og ra ni čen unos ka lo ri ja, sma nje nje te ži ne i tje les na 
ak tiv no st po bolj ša va ju in zu lin sku os jet lji vo st (2, 3, 7).
U ra du se ob jaš nja va ju me ha niz mi IR ko ji uk lju ču ju: po re-
me će no lu če nje adi po ki na i po ve ćan do tok FFA iz sre diš-
njeg mas nog tki va, te dru ge po re me ća je in zu lin skih pred-
re cepto ra, re cep to ra i pos tre cep to ra.
Me ha niz mi in zu lin ske re zis ten ci je
Fak tor tu mor ske nek ro ze α i slo bod ne mas ne ki se li ne
Ud ru že no st IR s po vi še nim fak to rom tu mor ske nek ro ze α 
(en gl. tumor nec ro sis fac tor α, TNF-α), in ter leu ki nom 
6 (IL-6), mak ro fa zi ma i mo no cit nim ke moat rak tan tnim 
pro tei no m-1 (en gl. mono cyte che moat trac ta nt pro tei n-
1, MCP-1), in hi bi to ro m-1 ak ti va to ra plaz mi no ge na (en gl. 
plas mi no gen ac ti va tor in hi bi to r-1, PAI-1), adip si nom te sni-
že nim adi po nek ti nom ut vr đe na je u mno gim stu di ja ma 
(8). IR je pop rat no obi ljež je u mno gih pre ti lih bo les ni ka. 
Mas no tki vo ot puš ta ve li ke ko li či ne TNF-α, ko ji je ba rem 
dje lo mi ce od go vo ran za raz voj IR kod pre ti los ti (9). S dru-
ge stra ne, poz na to je da se s gu bit kom na te ži ni po ve ća va 
in zu lin ska os jet lji vo st; smat ra se ka ko to me di je lom pos-
re du je sma nje no lu če nje adi poz nog TNF-α (10). TNF-α je 
glav ni au tok ri ni/parakrini čim be nik ko ji pok re će lu če nje 
slo bod nih mas nih ki se li na (FFA) iz mas nog tki va u kr vo tok 
(9). Me đu tim, os ta je ne jas no ko ji čim be ni ci dois ta pok re-
ću ot puš tanje adi po ki na iz mas nog tki va.
TNF-α pos re du je po tis ki va nje mno gih ge na od go vor nih 
za preu zi ma nje i poh ra nu glu ko ze i FFA. Za adi po ci te 
3T3-L1 je po ka za no ka ko se re gu la ci ja na vi še i na ni že ge-
na ovis nih o TNF-α od vi ja ob vez nim ak ti vi ra njem fak to ra 
nuk lear ne tran skrip ci je κB (11). Dje lo va njem TNF-α do la zi 
do po ja ča ne li po li ze uz ot puš ta nje FFA i ci to ki na.
TNF-α i FFA re me te in zu lin sko sig na li zi ra nje u tki vi ma 
ko ja od go va ra ju na in zu lin, pog la vi to u mi ši ći ma. Pre ma 
hi po te zi o opskr bi li pi di ma (Ran dleo va hi po te za), ot puš-
te ne FFA dje lu ju kao prev la da va ju ći sup strat u in ter me di-
stant rate and glucose is held at basal levels by glucose 
infusion. The rate of the latter is a measure of all tissues’ 
glucose uptake (4). Alternative measures of IR are fasting 
plasma insulin concentrations (2) and homeostasis model 
assessment (HOMA) derived from fasting plasma insulin 
and glucose concentrations (5).
The etiology of IR includes genetic factors resulting in 
syndromic forms of IR, and environmental factors: food 
intake, poor physical activity, aging, smoking or admin-
istration of drugs – thiazide diuretics, beta adrenergic 
antagonists and glucocorticoids, which can cause or 
contribute to IR (2). The most important factor is obesity, 
which is usually of combined polygenetic and environ-
mental origin (2, 6). Abdominal adipose tissue is a source 
of free fatty acids (FFA) and various hormones (adipo-
kines) implicated in the development of IR. Conversely, 
restricted calorie intake, weight reduction and physical 
activity improve insulin sensitivity (2, 3, 7).
The present paper explains the mechanisms of IR which 
include disregulated secretion of adipokines and in-
creased effl  ux of FFA from central adipose tissue, and 
other insulin prereceptor, receptor and postreceptor im-
pairments.
The Mechanisms of Insulin Resistance
Tumor necrosis factor α and free fatty acids
Numerous studies have found associations between 
increased tumor necrosis factor α (TNF-α), interleukin 6 
(IL-6), macrophages and monocyte chemoattractant pro-
tein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), 
adipsin, and decreased adiponectin with IR (8).
In the majority of obese patients IR is an accompanying 
feature. Adipose tissue releases great amounts of TNF-α, 
which is at least partly responsible for the development 
of IR in obesity (9). On the other hand, weight loss is well 
known to increase insulin sensitivity, which is thought to be 
mediated in part by decreased adipose TNF-α release (10). 
TNF-α is the main autocrine/paracrine factor triggering the 
secretion of FFA from adipose tissue into the circulation (9). 
However, it remains unclear which factors actually trigger 
the release of adipokines from adipose tissue.
TNF-α mediates repression of many genes responsible 
for glucose and FFA uptake and storage. For 3T3-L1 adi-
pocytes it has been shown that TNF-α dependent gene 
up- and down-regulation occurs by obligatory activation 
of nuclear transcription factor κB (11). Upon TNF-α action, 
enhanced lipolysis occurs with the release of FFA and cy-
tokines.
TNF-α and FFA impair insulin signaling in insulin respon-
sive tissues, especially muscle. The released FFA, accord-
ing to the lipid supply hypothesis (Randle hypothesis), act 
as a predominant substrate in intermediary metabolism. 
Increased NADH/NAD+ and acetyl-CoA/CoA ratios could 
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jar nom me ta bo liz mu. Po vi še ni om je ri NADH/NAD+ i ace-
ti l-CoA/CoA mog li bi bi ti raz lo gom sma nje nog preu zi ma-
nja glu ko ze, što zna či po re me će ne in zu lin ske os jet lji vos ti 
(12, 13). Vis ce ral no mas no tki vo lu či FFA iz rav no u por tal ni 
kr vo tok, či me snaž no ut je če na jet ru, a ne na pot kož no 
mas no tki vo ot puš ta ju ći svo je proiz vo de u pe ri fer nu cir ku-
la ci ju (1).
U jet ri ve li ke ko li či ne FFA osi gu ra va ju obi lan sup strat za 
sin te zu trig li ce ri da i VLDL, te za glu koneo ge ne zu. TNF-α 
po tis ku je ge ne za preu zi ma nje glu ko ze i be ta ok si da ci ju 
(14). Do la zi do de no vo sin te ze ko les te ro la, po tom do re gu-
la ci je na vi še od go va ra ju ćih ge na po mo ću TNF-α (8).
FFA ta ko đer pok re ću sin te zu fi b ri no ge na i PAI-1 u jet ri 
(15). FFA ko je iz vis ce ral nog mas nog tki va ot je ču u por tal-
nu cir ku la ci ju i u jet ru sma nju ju jet re ni kli re ns in zu li na, či-
me dop ri no se hi pe rin zu li ne mi ji (13). Su vi šak trig li ce ri da 
se na kup lja u jet ri (1). U mi ši ći ma pak vi so ke kon cen tra ci je 
FFA po go du ju be ta ok si da ci ji, či me se sma nju je preu zi ma-
nje i ok si da ci ja glu ko ze (16). No, be ta ok si da ci ja je ne dos-
tat na za dje lot vor no uk la nja nje FFA iz kr vo to ka, oso bi to 
ako ne ma tje les ne ak tiv nos ti (17). Sin te za gli ko ge na u mi-
ši ći ma je sus preg nu ta. Mišić ima glav nu ulo gu u uk la nja-
nju glu koze (80–90%), pa nje zi no sma nje no preu zi ma nje 
u ve li koj mje ri dop ri no si hi per gli ke mi ji (9, 18). Su viš ne FFA 
poh ra nju ju se kao kap lji ce trig li ce ri da u mi ši ći ma (1, 7, 17).
U mas nom tki vu FFA suz bi ja ju ak tiv no st li pop ro tein li pa-
ze, ko ju ina če po ti če in zu lin, te ta ko one mo gu ća va ju kli re-
ns FFA iz kr vo to ka (19). Sve u sve mu, li pi di ot puš te ni iz adi-
po ci ta kao FFA pre no se se kao trig li ce ri di po mo ću VLDL i 
prem ješ ta ju u ne mas na tki va (20).
Po ka za no je ka ko TNF-α na ni že re gu li ra ge ne za adi po-
nek tin, tran spor ter glu ko ze 4 (en gl. glu co se tran spor ter 
4, GLU T4), sup stra t-1 in zu lin skog re cep to ra (en gl. in su lin 
re cep tor sub stra te-1, I R S-1), CCAAT/po ja čaj ni vez ni pro tein 
α (en gl. CCAAT/enhancer bin di ng pro tein α, C/EBP-α), pe-
rok si zom ni pro li fe ra to r-ak ti vi ra ni re cep tor γ (en gl. pe roxi-
so me pro li fe ra to r-ac ti va ted re cep tor γ, PPA R-γ) i pe ri li pin u 
adi po ci ti ma (11, 14). TNF-α na vi še re gu li ra mno ge ge ne iz-
ra že ne u mas nom tki vu, ko ji su od go vor ni za upa lu, imu ni 
od go vor i ener get sku rav no te žu (vas ku lar na sta nič na pria-
nja ju ća mo le ku la-1 (VCA M-1), PAI-1, IL-6, IL-1β, an gio ten zi-
no gen, re zis tin, lep tin) (14).
Lep tin
Lep tin je hor mon što ga u naj ve ćoj mje ri lu či mas no tki vo, 
a oz na ča va dos tat nu ko li či nu ener gi je. Lep tin sma nju je 
unos hra ne i po ve ća va pot roš nju ener gi je (21). Ovi učin ci 
nas tu pa ju dje lo va njem lep ti na na hi po ta la mus i iz rav no 
na cilj na tki va (mi šić, go na de, β-sta ni ce, jet ru) (22).
U nor mal nim uv je ti ma od r ža va nja te ži ne kon cen tra ci je 
lep ti na po zi tiv no ko re li ra ju s ukup nom tje les nom mas-
nom ma som. Kod krat kot raj nog us kra ći va nja hra ne se-
rum ske ra zi ne lep ti na se sni ža va ju, dok se ob r nu to do ga-
đa kod krat kot raj nog pre kom jer nog hra nje nja (23).
be the reason for the decreased glucose uptake, which 
means impaired insulin sensitivity (12, 13). Visceral adi-
pose tissue secretes FFA directly to the portal blood fl ow 
thereby exerting potent eff ects on the liver rather than 
subcutaneous adipose tissue releasing its products to 
peripheral circulation (1).
In the liver, high amounts of FFA provide an abundant 
substrate for triglyceride and VLDL-synthesis, and gluco-
neogenesis. TNF-α represses genes for glucose uptake 
and beta oxidation (14). De novo cholesterol synthesis oc-
curs followed by TNF-α up-regulation of the correspond-
ing genes (8).
FFA also trigger fi brinogen and PAI-1 synthesis in the liver 
(15). FFA draining from visceral adipose tissue to portal 
circulation and to the liver decrease hepatic insulin clear-
ance, thereby contributing to hyperinsulinemia (13). Ex-
cess triglycerides are accumulating in the liver (1).
In the muscle, high FFA concentrations favor beta oxida-
tion, which diminishes glucose uptake and oxydation 
(16). However, beta oxidation is inadequate to clear FFA 
effi  ciently from the circulation, even more in the lack of 
physical activity (17). Glycogen synthesis in the muscle is 
inhibited. Muscle is in force as the main glucose disposer 
(80%–90%) and diminished uptake contributes largely to 
hyperglycemia (9, 18). Excess FFA are stored as triglycer-
ide droplets in the muscle (1, 7, 17).
In adipose tissue, FFA inhibit lipoprotein lipase activ-
ity which is otherwise stimulated by insulin, and thereby 
render clearance of FFA from circulation impossible (19). 
Overall, lipids released from adipocytes as FFA are trans-
ported as triglycerides by VLDL and shifted to non-adi-
pose tissues (20).
TNF-α has been shown to down-regulate the genes for 
adiponectin, glucose transporter 4 (GLUT4), insulin recep-
tor substrate-1 (IRS-1), CCAAT/enhancer binding protein 
α (C/EBP-α), peroxisome proliferator-activated receptor 
γ (PPAR-γ) and perilipin in adipocytes (11, 14). TNF-α up-
regulates many genes expressed in adipose tissue, which 
are responsible for infl ammation, immune response 
and energy balance (vascular cell adhesion molecule-1 
(VCAM-1), plasminogen activator inhibitor-1 (PAI-1), IL-6, 
IL-1β, angiotensinogen, resistin, leptin) (14).
Leptin
Leptin is a hormone secreted predominantly by adipose 
tissue and is a signal of energy suffi  ciency. It decreases 
food intake and increases energy expenditure (21). 
These eff ects are mediated by leptin action on the hypo-
thalamus and directly on target tissues (muscle, gonads, 
β-cells, liver) (22). In normal conditions of weight main-
tenance leptin concentrations positively correlate with 
total body fat mass. In short term food deprivation serum 
leptin levels decrease and the opposite is true for short 
term overfeeding (23).
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Lep tin pred stav lja bi tan čim be nik fer ti li te ta, jer se je po ka-
za lo ka ko su sni že ne kon cen tra ci je lep ti na na kon us kra ći-
va nja hra ne od go vor ne za suz bi ja nje hi po ta la mo-hi po fi z-
no-go nad ne osi (24).
Kli nič ka sta nja sa sma nje nom mas nom ma som (li po dis-
tro fi  je) obi lje že na su sni že nim kon cen tra ci ja ma lep ti na u 
plaz mi i IR. Da va njem lep ti na zna čaj no se po bolj ša va in-
zu lin ska os jet lji vo st u ovim sta nji ma (25), što po ka zu je da 
je nor mal na ko li či na mas nog tki va pre sud na za nor mal nu 
in zu lin sku os jet lji vo st, a to se ba rem dje lo mi ce is pu nja va 
kroz lu če nje lep ti na i nje go vim učin ci ma.
Va žan uči nak lep ti na je sim pa tič ka sti mu la ci ja pu tem neu-
ro na ko ji od go va ra ju na lep tin u hi po ta la mu su (8). To bi 
mog lo dje lo mi ce ob jas ni ti raz voj hi per ten zi je kod vis ce-
ral ne pre ti los ti te u nep re ti lim sta nji ma. U skla du s tim, mi-
šić na sim pa tič ka ak tiv no st kod nep re ti lih nor mo ten ziv nih 
muš ka ra ca dob ro ko re li ra s kon cen tra ci ja ma lep ti na ve za-
nog za bje lan če vi ne (26).
Adi po nek tin
Adi po nek tin po ka zu je snaž nu ob r nu tu ko re la ci ju s IR 
u li po dis tro fi  ji i pre ti los ti, te s upal nim sta nji ma (27, 28). 
Adi po nek tin lu če is klju či vo adi po ci ti (27). Adi po nek tin po-
bolj ša va in zu lin sku os jet lji vo st kroz ra zliči te me ha niz me. 
U jet ri iza zi va ok si da ci ju mas nih ki se li na, sma nju je sin te-
zu li pi da, sma nju je preu zi ma nje FFA i suz bi ja glu ko neo ge-
ne zu re gu li ra ju ći en zi me na ni že (8, 23, 29). U mi ši ću adi-
po nek tin po go du je ok si da ci ji glu ko ze i FFA. Ove učin ke 
di je lom omo gu ću je ak ti vi ra nje A MP-ki na ze (28). Ta ko adi-
po nek tin sni ža va razine FFA i glu ko ze u plaz mi (8, 23). Ka-
ta bo li zam FFA se po ti če iz rav no ili kroz po ti ca nje nuk lear-
nih re cep to ra PPA R-γ (30).
Adi po nek tin sma nju je iz ra že no st pria nja ju ćih mo le ku la 
na sti jen ci kr vnih ži la, suz bi ja ke mo tak su mak ro fa ga i nji-
ho vu pret vor bu u pje nas te sta ni ce, pro li fe ra ci ju glat ko-
mi šić nih sta ni ca i upal ne do ga đa je u ate ro ge ne zi što ih 
pro mi ču IL-6, PAI-1 itd. (8). Adi po nek tin ta ko đer suz bi ja lu-
če nje TNF-α (31).
Ra zi ne adi po nek ti na po ve ćava ju se s gu bit kom te ži ne (32) 
i li je če njem tia zo li di ne dio ni ma (en gl. thia zo li di ne dio nes, 
TZD) (33), ko ji su ago nis ti PPA R-γ. Sin te za adi po nek ti na je 
po re me će na u sta nji ma su viš ka ka lo ri ja, što bi mog lo bi ti 
po ve za no s re zis ten ci jom ili ne dos tat kom lep ti na (23). In-
zu lin i in zu li nu sli čan fak tor ras ta (en gl. in su li n-li ke growth 
fac to r-1, I GF-1) po ti ču sin te zu adi po nek ti na (23).
Slič no to me, IL-10 is to ta ko ima an ti di ja be to ge ni uči nak: 
kod pre ti los ti bez me ta bo lič kog sin dro ma ra zi ne IL-10 u 
plaz mi su po vi še ne, ali je IL-10 sni žen u me ta bo lič kom sin-
dro mu (34).
Re zis tin
Vis ce ral no mas no tki vo lu či re zis tin u da le ko ve ćoj mje ri 
ne go pot kož no mas no tki vo (8). Kod pre ti los ti u glo da va-
ca su se rum ske ra zi ne re zis ti na po vi še ne, a ne ki su po ku si 
Leptin represents an essential fertility factor as decreased 
leptin concentrations following food deprivation have 
been shown to be responsible for the suppression of the 
hypothalamic-pituitary-gonadal axis (24).
Clinical states with diminished adipose mass (lipodys-
trophies) are characterized by reduced plasma leptin 
concentrations and IR. Leptin administration signifi cantly 
improves insulin sensitivity in these conditions (25), indi-
cating that normal amount of adipose tissue is critical for 
normal insulin sensitivity, and this is at least partly fulfi lled 
via leptin secretion and its eff ects.
An important leptin eff ect is sympathetic stimulation 
achieved by eliciting leptin-responsive neurons in the 
hypothalamus (8). This could in part explain the develop-
ment of hypertension in visceral obesity and non-obese 
states. In accordance with this, muscle sympathetic activ-
ity in non-obese normotensive men correlates well with 
protein-bound leptin concentrations (26).
Adiponectin
Adiponectin shows strong inverse correlation to IR in 
lipodystrophy and obesity, and to infl ammatory states 
(27, 28). It is secreted exclusively by adipocytes (27). Adi-
ponectin improves insulin sensitivity by various mecha-
nisms: in the liver, it induces fatty acid oxidation, decreas-
es lipid synthesis, decreases uptake of FFA and represses 
gluconeogenesis by enzyme down-regulation (8, 23, 29). 
In muscle, adiponectin favors glucose and FFA oxidation. 
These eff ects are partly due to the activation of AMP-
kinase (27). Thereby, adiponectin decreases plasma FFA 
and glucose levels (8, 23). FFA catabolism is stimulated 
either directly or through stimulation of PPAR-γ nuclear 
receptors (30).
Adiponectin decreases the expression of adhesion mol-
ecules on blood vessel wall, inhibits chemotaxis of mac-
rophages and their conversion to foam cells, prolifera-
tion of smooth muscle cells and infl ammatory events in 
atherogenesis, which are promoted by IL-6, PAI-1 etc. (8). 
Adiponectin also suppresses secretion of TNF-α (31).
Adiponectin levels increase with weight loss (32) and 
treatment with thiazolidinediones (TZD) (33), which are 
PPAR-γ agonists. The synthesis of adiponectin is impaired 
in the states of calorie excess, which might be associ-
ated with leptin resistance or defi ciency (23). Insulin and 
insulin-like growth factor (IGF-1) stimulate adiponectin 
synthesis (23).
Similarly, IL-10 also exerts an antidiabetogenic eff ect: in 
obesity without the metabolic syndrome IL-10 plasma 
levels are increased, but in the metabolic syndrome IL-10 
is decreased (34).
Resistin
Resistin is secreted to a much greater extent by visceral 
than by subcutaneous adipose tissue (8). In rodent obe-
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pot vr di li da re zis tin uz ro ku je IR (35). Me đu tim, dru ga pak 
is pi ti va nja ni su pot vr di la tak ve re zul ta te (8, 36).
Ljud ski re zis tin po ka zu je tek 64%-tnu ho mo log no st s re-
zis ti nom glo da va ca (37) i iz ra že no st re zis ti na u ljud skim 
adi po ci ti ma ni je jed na ko ud ru že na s IR ili pre ti loš ću (23). 
S dru ge stra ne, tia zo li di ne dio ni (TZD) mož da svo je učin ke 
dje lo mi ce os tva ru ju kro za sma nje no dje lo va nje re zis ti na, 
jer se nje go vo lu če nje sma nju je ti je kom li je če nja TZDi ma 
(23). Sve u sve mu, ulo gu re zis ti na u lju di tek tre ba pod rob-
ni je raz jas ni ti.
Os ta li adi po ki ni
Mak ro fa zi i mo no cit ni ke moat rak tan tni pro tei n-1 (MCP-1) 
su iz rav no uz roč no po ve zani s IR: MCP-1 re me ti ula zak glu-
ko ze i in zu lin ske sig na le u sta ni ca ma (38). Adi po ci ti lu če 
MCP-1; on priv la či mak ro fa ge u mas no tki vo i pro mi če nji-
ho vo ot puš tanje IL-1 i TNF-α (8). On is to ta ko suz bi ja ra st 
i di fe ren ci ja ci ju adi po ci ta. MCP-1 pro mi če ate ros kle ro zu 
priv la če ći mak ro fa ge i po go du ju ći nji ho vom na kup lja nju 
u sta nič nim sti jen ka ma (39).
PAI-1 je vi še iz ra žen u vis ce ral nom u us po red bi s pot kož-
nim mas nim tki vom (40). On je snaž no ud ru žen s vis ce ral-
nom pre ti loš ću, IR i me ta bo lič kim sin dro mom. Pret pos tav-
lja se da PAI-1 dop ri no si pre ti los ti i IR, te da ima uz roč nu 
ulo gu u dalj njem raz vo ju kar dio vas ku lar ne bo les ti zbog 
svog prot rom bot skog dje lo va nja (8). Ra zi ne PAI-1 u plaz-
mi sni ža va ju se s gu bit kom te ži ne (8) i li je če njem tva ri ma 
za in zu lin sku sen zi bi li za ci ju (41).
Stu di je s IL-6 uka zu ju na nje go vu uz roč nu ulo gu u IR, jer 
plaz mat ske kon cen tra ci je i iz ra že no st u mas nom tki vu te 
po li mor fi  zam IL-6 dob ro ko re li ra ju s pre ti loš ću i IR. Po ka-
za no je ka ko IL-6 re me ti in zu lin sko sig na li zi ra nje (42), suz-
bi ja adi po ge ne zu i lu če nje adi po nek ti na (8). Is to ta ko, IL-6 
iza zi va IR u jet ri i adi po ci ti ma (43).
U sre diš njem živ ča nom sus ta vu IL-6 ima sup rot ne učin ke 
– što uka zu je na to da on po go du je pot roš nji ener gi je. Da-
va nje IL-6 tran sge nič nim glo dav ci ma ko ji ma je uk lo njen 
gen za IL-6 po niš tio je raz voj pre ti los ti (44).
Glu ko kor ti koi di
Glu ko kor ti koi di su dob ro poz na ti an ta go nis ti in zu li na. Oni 
se sup rot stav lja ju učin ci ma in zu li na i ti me mo gu izaz va ti 
IR. Oni dje lu ju na ob je ma ra zi na ma IR: po ja ča va ju jet re nu 
glu ko neo ge ne zu i ot puš ta nje glu ko ze iz jet re, te re me te 
preu zi ma nje glu ko ze u pe ri fer nim tki vi ma. Pret hod no 
spo me nu te vi so ke ra zi ne FFA pred stav lja ju me ha ni zam 
za ovaj po to nji uči nak, a naj ma nje su tri mo gu ća pu ta ko ji-
ma mo že nas tu pi ti li po li za:
1. glu ko kor ti koi di po ve ća va ju pret vor bu no rad re na li na 
u ad re na lin (fe ni l-e ta no la min N-me til tran sfe ra za u ske-
let nim mi ši ći ma), ko ji dje lu je na hor mon ski os jet lji vu 
li pa zu u mas nom tki vu i provo di li po li zu (45);
2. oni pos re du ju li po li zu kroz re gu li ra nje na vi še PPA R-γ 
(46);
sity, serum resistin levels are increased and some experi-
ments have confi rmed resistin as causing IR (35). However, 
some other studies failed to confi rm these results (8, 36).
Human resistin shows only 64% homology with rodent re-
sistin (37) and expression of resistin in human adipocytes 
is not uniformly associated with IR or obesity (23). On the 
other hand, TZD may exert their eff ects partly through a 
diminished action of resistin as its secretion is decreased 
during TZD therapy (23). Taken together, the role of resis-
tin in humans remains to be further elucidated.
Other adipokines
Macrophages and monocyte chemoattractant protein-1 
(MCP-1) are directly causally associated with IR: MCP-1 im-
pairs glucose entrance and insulin signaling in cells (38). 
MCP-1 is secreted by adipocytes; it attracts macrophages 
to adipose tissue and promotes their IL-1 and TNF-α 
release (8). It also inhibits adipocyte growth and diff er-
entiation. MCP-1 promotes atherosclerosis by attracting 
macrophages and favoring their accumulation in vessel 
walls (39).
PAI-1 has higher expression in visceral compared to sub-
cutaneous adipose tissue (40). It is strongly associated 
with visceral obesity, IR and metabolic syndrome. PAI-1 is 
hypothesized to contribute to obesity and IR, and has a 
causal role in further development of cardiovascular dis-
ease for its prothrombotic activity (8). PAI-1 plasma levels 
decrease after weight loss (8) and therapy with insulin 
sensitizing substances (41).
Studies with IL-6 have suggested its causal role in IR, as 
plasma concentrations and adipose tissue expression, and 
polymorphisms of IL-6 correlate well with obesity and IR. 
IL-6 was shown to interfere with insulin signaling (42), and 
to inhibit adipogenesis and secretion of adiponectin (8). 
IL-6 also induces IR in the liver and adipocytes (43).
In the central nervous system IL-6 has opposite eff ects 
– suggesting that it favors energy expenditure. Admin-
istration of IL-6 to IL-6 gene knockout rodents reversed 
obesity (44).
Glucocorticoids
Glucocorticoids are well known insulin antagonists. They 
oppose the eff ects of insulin and thereby could induce 
IR. They act on both levels of IR: they enhance liver glu-
coneogenesis and glucose release, and impair glucose 
uptake by peripheral tissues. The mechanism for the lat-
ter are previously mentioned high levels of FFA, and there 
are at least three possible ways how lipolysis can occur:
1. glucocorticoids increase norepinephrine conversion 
to epinephrine (phenyl-ethanolamine N-methyltrans-
ferase in skeletal muscle), which acts on hormone sen-
sitive lipase in adipose tissue and performs lipolysis 
(45);
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3. oni suz bi ja ju li pop ro tein li pa zu i ti me one mo gu ća va ju 
preu zi ma nje FFA u mas nom tki vu (47).
U ske let nim mi ši ći ma je po ka za na po re me će na tran slo ka-
ci ja GLU T4 kao pos lje di ca dje lovanja glu ko kor ti koi da (48). 
Po ka za no je ka ko glu ko kor ti koi di suz bi ja ju va zo di la ta ci ju 
(izaz va nu in zu li nom pu tem du šič nom ok si da), pa su ta da 
cilj na tki va do bi va la ma nje glu ko ze (49). Ove učin ke glu ko-
kor ti koi da još po ja ča va ju FFA po ve ća nim ve za njem glu ko-
ko rtikoi da za nji ho ve re cep to re (50).
Mo le ku lar ni me ha niz mi po re me će nog in zu-
lin skog sig na li zi ra nja
Nor mal no in zu lin sko sig na li zi ra nje
In zu lin ski re cep tor je he te ro tet ra mer ni re cep tor ko ji je 
iz ra žen na jet re nim, adi poz nim i ske let no mi šić nim sta ni-
ca ma. Ve za nje in zu li na pok re će oli go me ri za ci ju i au to fos-
fo ri la ci ju re cep to ra na ti ro zin skim os ta ci ma, te ti ro zin sku 
fos fo ri la ci ju I R S-1, -2, -3, -4, IR S5/DOK4, IR S6/DOK5. Ova 
fos fo ri la ci ja či ni os no vu za dalj nje ud ru ži va nje s niz vod-
nim sig nal nim bje lan če vi na ma ko je se ra zi la ze u tri raz li či-
te pu ta nje: pu ta nju fos foi no zi ti d-3-ki na zu (en gl. phos phoi-
no si ti de-3-ki na se, PI3K), pu ta nju CAP/Cbl/TC10 i pu ta nju 
ovis nu o mi to ge nom ak ti vi ra noj pro tein ki na zi (en gl. mi to-
ge n-ac ti va ted pro tein ki na se, MA P-ki na se) (Sli ka 1.) (51, 52). 
PI3K uza jam no dje lu je s fos fo ri li ra nim Tyr na mo le ku le IRS 
te se na kon stva ra nja fos fa ti di li no zi to l-3,4,5-trifosfata (en-
gl. phos pha ti dyli no si to l-3,4,5-triphosphat, PIP3) ak ti vi ra ju 
raz li či te pro tein ki na ze (53). Pos lje dič no to me do la zi do 
deak ti vi ra nja gli ko gen sin ta ze ki na ze 3 (en gl. glyco gen 
syntha se ki na se 3, GSK-3), što na kon cu re zul ti ra sin te zom 
gli ko ge na; gen sin ta ze mas nih ki se li na re gu li ran je na vi še, 
dok je gen fos foe nol pi ru vat kar bok si ki na ze (en gl. phos-
phoe nol pyru va te car boxyki na se, PEPCK) re guli ran na ni že. 
Bi tan uči nak pu ta PI3K je tran slo ci ra nje glav nog pri je nos-
ni ka glu ko ze GLU T4 u plaz mat sku mem bra nu (51, 52). Sin-
te za bje lan če vi na nas tu pa ak ti vi ra njem cilj nog en zi ma za 
ra pa mi cin ko ji je svoj stven si sav ci ma (en gl. mam ma lian 
tar get of ra pa mycin, mTOR) (54).
Ka ko bi se preu zi ma nje glu ko ze od vi ja lo u pot pu nos ti, pri-
la god be na bje lan če vi na CAP upoš lja va pro to-on ko gen 
Cbl u fos fo ri li ra ni in zu lin ski re cep tor, što u ko nač ni ci do vo-
di do po ja ča ne tran slo ka ci je GLU T4 (51).
Tre ći put do vo di do ak ti vi ra nja MA P-ki na ze te sta nič ne 
pro li fe ra ci je i di fe ren ci ja ci je pu tem re gu la ci je gen ske tran-
skrip ci je (52, 55).
Ne dos tat ci u in zu lin skom sig na li zi ra nju
Ma nji broj slu ča je va in zu lin ske re zis ten ci je obi lje žen je 
po jed nom ge net skom ili ste če nom zna čaj kom. Pro tuin-
zu lin ska au toan ti ti je la na đe na su kod še ćer ne bo les ti tipa 
1. (56). S dru ge stra ne, u ge nu in zu lin skih re cep to ra ut vr-
đe no je vi še od 60 mu ta ci ja. Me đu nji ma je IR tip A ud ru-
žen sa sta njem he te ro zi got ne mu ta ci je, ko je či ni os no vu 
2. they mediate lipolysis via up-regulation of PPAR-γ 
(46); and
3. they inhibit lipoprotein lipase and thus disable the 
uptake of FFA by adipose tissue (47).
In skeletal muscle impaired translocation of GLUT4 was 
shown as a consequence of glucocorticoid action (48). 
Glucocorticoids were shown to inhibit vasodilatation 
(induced by insulin via nitrogen oxide) and less glucose 
was then delivered to target tissues (49). These eff ects of 
glucocorticoids are even potentiated by FFA increasing 
glucocorticoids binding to their receptors (50).
Molecular Mechanisms of Impaired Insulin 
Signaling
Normal insulin signaling
Insulin receptor is a heterotetramer receptor, which is 
expressed on the liver, adipose and skeletal muscle cells. 
Binding of insulin triggers oligomerization and receptor 
autophosphorylation on tyrosine residues and tyrosine 
phosphorylation of IRS-1, -2, -3, -4, IRS5/DOK4, IRS6/DOK5. 
This phosphorylation provides the base for following as-
sociation with downstream signal proteins which diverge 
into three diff erent pathways: phosphoinositide-3-kinase 
(PI3K) pathway, CAP/Cbl/TC10 pathway and mitogen-ac-
tivated protein kinase (MAP-kinase) dependent pathway 
(Fig. 1) (51, 52). PI3K interacts with phosphorylated Tyr on 
IRS molecules and upon formation of phosphatidylino-
sitol-3,4,5-triphosphate (PIP3) various protein kinases 
are activated (53). As a consequence, glycogen synthase 
kinase 3 (GSK-3) is inactivated, which at the fi nal stage re-
sults in glycogen synthesis; the fatty acid synthase gene 
is up-regulated and phosphoenolpyruvate carboxykinase 
(PEPCK) gene is down-regulated. An essential eff ect of 
PI3K pathway is translocation of the main glucose trans-
porter GLUT4 to the plasma membrane (51, 52). Protein 
synthesis is activated via enzyme mammalian target of 
rapamycin (mTOR) activation (54). For glucose uptake to 
manifest fully, the adapter protein CAP recruits proto-on-
cogene Cbl to the phosphorylated insulin receptor, which 
fi nally results in reinforced GLUT4 translocation (51). The 
third pathway leads to MAP-kinase activation and cellular 
proliferation and diff erentiation via gene transcription 
regulation (52, 55).
Defects in insulin signaling
A minority of insulin resistant cases are characterized by a 
single genetic or acquired trait. Anti-insulin autoantibod-
ies have been found in diabetes mellitus DM type 1 (DM1) 
(56). On the other hand, more than 60 mutations have 
been identifi ed in the insulin receptor gene. Among them 
type A IR is associated with heterozygous mutation state 
which underlies decreased Tyr phosphorylation of the β-
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za sma nje nu fos fo ri la ci ju Tyr u β-pod je di ni ci na kon ve za-
nja in zu li na (57). Pret pos tav lja se da mu ta ci je ge na in zu-
lin skih re cep to ra kod Rab so n-Men den hal lo va sin dro ma 
i Do no hue va sin dro ma re me te ve za nje in zu li na za re cep-
tor (57). IR mož da nas ta je zbog ne nor mal ne proiz vod nje 
pro tu ti je la za pro tuin zu lin ske re cep to re (IR tip B) (58). Za 
mu ta ci je PPA R-γ ko je ni su ud ru že ne s li po dis tro fi  jom ta ko-
đer se iz vješ ta va da uz ro ku ju IR (59).
Ne ki au to ri iz vješ ta va ju o po ve ća noj raz grad nji in zu lin-
skih re cep to ra (60). Uz to, pret pos tav lja se ka ko bi fos fo-
ri la ci ja se ri na/treonina raz nim pro tein ki na za ma C (en gl. 
pro tein ki na se C, PKC) mog la bi ti do dat nim čim be ni kom 
FI GU RE 1. In su lin sig nal tran sduc tion (51-55). Af ter in su lin re cep tor 
Tyr au top hos pho ryla tion, in su lin re cep tor sub stra tes 1 to 4 (I R S-1 to 
4) Tyr phor pho ryla tion ta kes pla ce and sub sequen tly three diff e re nt 
pat hways tran sdu ce the sig nal: PI3K-de pen de nt pat hway me dia ti ng 
me ta bo lic res pon ses in clu di ng glu co se/lipid/protein me ta bo li sm and 
in su li n-sti mu la ted glu co se up ta ke; CAP/Cbl pat hway whi ch is ad di tio-
nal ly requi red for glu co se tran spor te r-4 (GLU T4) tran slo ca tion; and 
mi to ge n-ac ti va ted pro tein ki na se (MAPK) pat hway re sul ti ng in ce ll 
pro li fe ra tion and diff e ren tia tion. So lid li ne: sti mu la tion; das hed li ne: 
in hi bi tion. IRS, in su lin re cep tor sub stra te; PI3K, phos phoi no si ti de-3-ki-
na se; PDK-1, phos phoi no si ti de-de pen de nt ki na se 1; PKB, pro tein ki na-
se B; aP KC, atypi cal pro tein ki na ses C; mTOR, mam ma lian tar get of ra pa-
mycin; p70S6K, p70 ri bo so mal S6 ki na se; PEPCK, phos phoe nol pyru va te 
car boxyki na se; GSK3, glyco gen syntha se ki na se 3.
subunit after insulin binding (57). In Rabson-Mendenhall 
syndrome and leprechaunism (Donohue syndrome) insu-
lin receptor gene mutations are presumed to impair insu-
lin binding to the receptor (57). IR may be due to abnor-
mal production of anti-insulin-receptor antibodies (type 
B IR) (58). PPAR-γ mutations which are not associated with 
lipodystrophy are also reported to cause IR (59).
Some studies report an increased degradation of insulin 
receptor (60). Besides, it is hypothesized that serine/threo-
nine phosphorylation by various protein kinases C (PKCs) 
could be an additional factor to regulate insulin receptor 
activity (61). Decreased Tyr phosphorylation state of IRS-1 
SLI KA 1. Pret vor ba in zu lin skih sig na la (51-55). Na kon Tyr au to fos fo ri-
la ci je in zu lin skih re cep to ra do la zi do Tyr fos fo ri la ci je sup stra ta za in zu-
lin ke re cep to re 1 to 4 (I R S-1 do -4), a po tom se sig nal pret va ra tri ma 
raz li či tim pu to vi ma: pu tom ovis nim o PI3K ko ji pos re du je me ta bo li čke 
od go vo re u ključu ju ći me ta bo li zam glu ko ze/lipida/bjelančevi na in zu li-
nom po ti ca no preu zi ma nje glu ko ze, pu tom CAP/Cbl ko je je do dat no 
pot re ban za tran slo ka ci ju pri je nos ni ka glu ko ze 4 (GLU T4) i pu tom mi-
to ge nom ak ti vi ra ne pro tein ki na ze (MAPK) ko ji re zul ti ra sta nič nom 
pro li fe ra ci jom i di fe ren ci ja ci jom. Pu na cr ta: po ti ca nje; is pre ki da na cr-
ta: suz bi ja nje. IRS, sup strat za in zu lin ske re cep to re; PI3K, fos foi no zi ti d-
3-ki na za; PDK-1, ki na za 1 ovis na o fos foi no zi ti du; PKB, pro tein ki na ze 
B; aP KC, ati pič ne pro tein ki na ze C; mTOR, cilj za ra pa mi cin u si sa va ca; 
p70S6K, p70 ri bo som na S6 ki na za; PEPCK, fos foe nol pi ru vat kar bok si ki-
na za; GSK3, gli ko gen sin ta za ki na za 3.
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re gu la ci je ak tiv nos ti in zu lin skih re cep to ra (61). Sta nje sma-
nje ne Tyr fos fo ri la ci je I R S-1, ko je je za pa že no kod hi pe rin-
zu li ne mič nih ob/ob mi še va, mog lo bi bi ti pos lje di ca sma-
nje nje ak tiv nos ti in zu lin skih re cep to ra (62).
No vi ja is pi ti va nja su ug lav nom us re do to če na na po ve ća-
nu Ser/Thr fos fo ri la ci ju I R S-1, ko ja bi mog la bi ti pos lje di-
ca po vi še nih kon cen tra ci ja TNF-α i da lje se po gor ša va hi-
pe rin zu li nemijom ko ju uz ro ku je IR. Smat ra se da su PKC, 
PI3K-dalj nje ki na ze i MA P-ki na ze od go vor ne za Ser/Thr 
fos fo ri la ci ju, na kon če ga sli je di po ja ča na pro tea zom na raz-
grad nja I R S-1. Nai me, sma njen sad r žaj I R S-1 bje lan če vi ne 
opi san je u lju di, ži vo ti nja i uz go je nim stani ca ma s IR (51).
Va lja nag la si ti ka ko je sta no vi to ba zal no sta nje Ser/Thr fos-
fo ri la ci je I R S-1 neop hod no za us pješ nu Tyr fos fo ri la ci ju i 
in zu lin sko sig na li zi ra nje. Za to preos ta je ras vi jet li ti ko ji je 
stu panj fos fo ri la ci je I R S-1 i na ko jim Ser/Thr mjes ti ma pot-
re ban da bi po ka zao svo je raz nov r sne učin ke.
Uz to što pos re du je raz grad nju I R S-1, hi pe rin zu li ne mi ja 
mo že ut je ca ti na kon cen tra ci ju bje lan če vi na u I R S-2 i izaz-
va ti ne ke prom je ne ni že na pu tu in zu lin ske sig na li za ci je (51).
TNF-α, IL-6 i in zu lin in du ci raju dru gu važ nu sku pi nu čim-
be ni ka IR – sup re so re ci to kin skog sig na li zi ra nja (en gl. sup-
pres so rs of cyto ki ne sig nal li ng-1-3, SO CS-1-3), ko ji ima ju naj-
ma nje tri raz li či ta me ha niz ma dje lo va nja: oni se nat je ču s 
I R S-1 za ud ru ži va nje s in zu lin skom re cep to rom, suzbija ju 
Ja nus ki na zu up le te nu u in zu lin sko sig na li zi ra nje i po ve ća-
va ju pro tea zom nu raz grad nju I R S-1 (63). Za hi per gli ke mi-
ju je po ka za no ka ko teš ko sma nju je ak tiv no st pro tein ki-
na ze B (en gl. pro tein ki na se B, PKB), ia ko su bi le ak ti vi ra ne 
ne ke dru ge prok si mal ne sas tav ni ce in zu lin ske sig na li za ci-
je (in zu lin ski re cep tor, I R S-1, I R S-2, PI3K).
Po ka za no je ka ko slo bod ne mas ne ki se li ne u vi so kim plaz-
mat skim kon cen tra ci ja ma kroz pret vor bu u dia cil gli ce rol 
i aci l-CoA sma nju ju ak tiv nos ti I R S-1, -2, te ak tiv nos ti PI3K 
i raz li či tih izo for ma PKB i PKC u mi ši ću šta ko ra (51). Kod 
tran sge nič nih mi še va FFA su po ve ća le ak tiv no st bje lan če-
vi ne Mun c18c, ne ga tiv nog re gu la to ra tran slo ka ci je GLU T4 
u plaz mat sku mem bra nu (64). Ipak, ne za si će ne FFA su ko-
ris ne uto li ko što omo gu ća va ju normal nu in zu lin sku os jet-
lji vo st u ne kim cilj nim tki vi ma (51).
Po ka za no je ka ko gli ci ra ne bje lan če vi ne, ko je nas ta ju kao 
pos lje di ca hi per gli ke mi je, unu tar sta ni ce sma nju ju ak tiv-
no st PI3K, PKB i GSK-3, te ta ko mož da dop ri no se IR. Slič no 
to me, glu ko za min (U DP-N-a ce til glu ko za min), ko ji nas ta je 
iz glu ko ze i pred stdav lja glav ni sup strat za sta nič nu gli ko-
zi la ci ju, po ja ča va gli ko zi la ci ju I R S-1 sma nju ju ći ta ko nje go-
vu ak tiv no st, te gli ko zi la ci ju gli ko gen sin ta ze, sma nju ju ći 
ta ko nje zi nu spo sob no st od go vo ra na in zu lin (51).
Pre ti lo st
Sta nje uh ra nje nos ti se naj bo lje opi su je po mo ću in dek sa 
tje les ne ma se (en gl. bo dy ma ss in dex, BMI). BMI se iz ra ču-
na va ta ko da se te ži na oso be u ki log ra mi ma po di je li kvad-
ra tom vi si ne u met ri ma. Uz ne ke iz nim ke BMI dob ro ko re-
that was found in hyperinsulinemic ob/ob mice could be 
a consequence of decreased insulin receptor activity (62).
Recent studies focus mainly on increased Ser/Thr phos-
phorylation of IRS-1, which could be a consequence of 
increased TNF-α concentrations and further exacerbated 
by hyperinsulinemia which is secondary to IR. PKCs, 
PI3K-downstream kinases and MAP-kinases are thought 
to be responsible for Ser/Thr phosphorylation, which is 
followed by enhanced proteasomal degradation of IRS-1. 
Namely, decreased IRS-1 protein content has been re-
ported in humans, animals and cultured cells with IR (51).
It is to emphasize that certain basal Ser/Thr phosphory-
lation state of IRS-1 is necessary for successful Tyr phos-
phorylation and insulin signaling. Therefore, it remains 
to be elucidated to which degree and on which Ser/Thr 
sites IRS-1 must be phosphorylated to display its diverse 
eff ects.
Besides mediating IRS-1 degradation, hyperinsulinemia 
might aff ect protein concentration of IRS-2 and provoke 
some downstream changes in insulin signaling (51).
TNF-α, IL-6 and insulin induce another important group 
of IR factors – suppressors of cytokine signaling (SOCS-1 
and -3), which have at least three diff erent mechanisms of 
action: they compete with IRS-1 for association with insu-
lin receptor, they inhibit Janus kinase, involved in insulin 
signaling, and they augment proteasomal IRS-1 degrada-
tion (63).
Hyperglycemia was shown to severely decrease protein 
kinase B (PKB) activity, although some other proximal 
components of insulin signaling (insulin receptor, IRS-1, 
IRS-2, PI3K) were activated.
FFA in high plasma concentrations were shown, by trans-
formation to diacylglycerol and acyl-CoA, to diminish the 
activities of IRS-1, -2 and activities of PI3K and various iso-
forms of PKB and PKC in rat muscle (51). In transgenic mice, 
FFA increased the activity of Munc18c protein, a negative 
regulator of GLUT-4 translocation to plasma membrane 
(64). Nevertheless, unsaturated FFA have benefi t to allow 
normal insulin sensitivity in some target tissues (51).
Glycated proteins, emerging as a consequence of hyper-
glycemia were shown intracellularly to diminish the PI3K, 
PKB, and GSK-3 activity, thus possibly contributing to IR. 
Similarly, glucosamine (UDP-N-acetyl glucosamine), pro-
duced from glucose and being the main substrate for cel-
lular glycosylation, enhances IRS-1 glycosylation thereby 
decreasing its activity, and glycogen-synthase glycosyl-
ation, which reduces its insulin responsiveness (51).
Obesity
The state of nutrition is best described by body mass in-
dex (BMI). BMI is calculated by dividing a person's weight 
in kilograms by the square of his height in meters. BMI 
is, with some exceptions, in good correlation with the 
amount of total body fat. According to BMI, the following 
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li ra s ko li či nom ukup ne tje les ne mas ti. Pre ma BMI ut vr đe-
ne su sli je de će ka te go ri je pre kom jer ne tje les ne ma se ili 
uh ra nje nos ti (65):
BMI 25-30 kg/m2 pre kom jer na te ži na
BMI 30-40 kg/m2 pre ti lo st
BMI 40-50 kg/m2 bo les na pre ti lo st
BMI >50 kg/m2 kraj nja pre ti lo st
In zu lin ska i lep tin ska re zis ten ci ja kod pre ti los ti
Vis ce ral na pre ti lo st pre dis po ni ra raz voj hi per ten zi je, še-
ćer ne bo les ti tipa 2, kar dio vas ku lar ne bo les ti i od re đe nih 
vr sta ra ka (66). Po ve ćan ri zik za zdrav lje pos to ji već i u sku-
pi ni pre kom jer ne te ži ne. Uz ukup nu tje les nu ma su mas ti, 
za mo gu će me ta bo lič ke kom pli ka ci je bit na je i ras pod je la 
mas ti. Vis ce ral no i pot kož no mas no tki vo raz li ku ju se pre-
ma nji ho vim en dok ri nim ak tiv nos ti ma. Spe ci fi č ni re cep-
to ri kao što su re cep to ri ti pa 1 an gio ten zi na II. (AT1), β1-, 
β2- i β3-ad re ner gič ni re cep to ri, re cep to ri glu ko kor ti koi da 
i an dro ge na zas tup lje ni su u ve ćoj mje ri u vis ce ral nom 
mas nom tki vu, gdje pro mi ču li po li zu (8, 67, 68). S dru ge 
stra ne, an ti li po li tič ni inzulin ski re cep to ri, α-2A ad re ner gič-
ni re cep to ri i es tro gen ski re cep to ri prev la da va ju u pot kož-
nom mas nom tki vu (67, 68). Uz to, vis ce ral no mas no tki vo 
lu či svo je proiz vo de u por tal nu cir ku la ci ju i ta ko do vo di 
os lo bo đe ne FFA iz rav no u jet ru gdje one on da po go du ju 
glu ko neo ge ne zi, sin te zi VLDL, sma nju ju preu zi ma nje glu-
ko ze i uz ro ku ju sveop ću IR.
Vis ce ral no mas no tki vo je obi lje že no re la tiv no vi so kim lu-
če njem IL-1 i PAI-1, dok je lu če nje lep ti na i adi po nek ti na 
ve će u pot kož nom mas nom tki vu (8). To je od go vor no za 
od nos iz me đu vis ce ral ne pre ti los ti i upal nih/trombotskih 
do ga đa ja, te ob jaš nja va učin ko vi to st TZD u po bolj ša nju 
in zu lin ske os jet lji vos ti kroz pre ras pod je lu li pi da u pot kož-
no mas no tki vo (69).
Kod pre ti lih oso ba su kon cen tra ci je lep ti na u plaz mi po vi-
še ne pa eg zo ge no da va nje lep ti na ne ma učin ka na tje les-
nu te ži nu (8). Ova se po ja va ob jaš nja va lep tin skom re zis-
ten ci jom ili de sen zi bi li za ci jom (23). Uz to, kod pre ti los ti su 
kon cen tra ci je top lji vog lep tin skog re cep to ra nis ke, a ti me 
i kon cen tra ci je frak ci je ve zanog lep ti na. Ovo obi ljež je je 
neo vis no ud ru že no s ab do mi nal nom pre ti loš ću i IR. Smat-
ra se ka ko top lji vi lep tin ski re cep to ri ima ju važ nu ulo gu 
u pri je no su u i kroz kr vno-mož da nu ba ri je ru, pa bi za si će-
no st ovo ga pri je no sa ili po re me ćaj u pret va ra nju sig na la 
lep tin skog re cep to ra mog li bi ti uz ro kom lep tin ske re zis-
ten ci je. Kon cen tra ci je lep ti na u ce reb ros pi nal noj te ku ći ni 
pre ti lih bo les ni ka tek su bla go po vi še ne (23).
Pa to fi  zio lo gi ja pre ti los ti
Sva ka oso ba ima ge net ski od re đe nu te žin sku struk tu ru 
ko jom se tje les na te ži na stro go re gu li ra ener get skim ho-
meos tat skim me ha niz mom (Sli ka 2.) (6, 66, 71). Adi po ci ti 
lu če lep tin, a β-sta ni ce lu če in zu lin, obo je raz mjer no sad-
r ža ju tje les ne mas ti. Ova dva hor mo na ula ze u mo zak; ve-
categories of excessive body mass or nutrition are postu-
lated (65):
BMI 25-30 kg/m2 overweight
BMI 30-40 kg/m2 obesity
BMI 40-50 kg/m2 morbid obesity
BMI >50 kg/m2 extreme obesity
Insulin and leptin resistance in obesity
Visceral obesity predisposes to the development of hy-
pertension, diabetes mellitus type 2 (DM2), cardiovascu-
lar disease, and certain types of cancer (66). An increased 
risk for health exists already in the overweight group. Be-
sides total body fat mass, distribution of fat is essential for 
eventual metabolic complications. Visceral and subcuta-
neous adipose tissues diff er in their endocrine activities. 
Specifi c receptors such as angiotensin II receptors type-1 
(AT1), β1-, β2-, β3-adrenergic receptors, glucocorticoid and 
androgen receptors are represented to a larger degree 
in visceral adipose tissue where they promote lipolysis 
(8, 67, 68). On the other hand, antilipolytic insulin recep-
tors, α-2A adrenergic receptors, and estrogen receptors 
are predominantly expressed in subcutaneous adipose 
tissue (67, 68). Additionally, visceral adipose secretes its 
products to the portal circulation, which brings the re-
leased FFA directly to the liver where they promote glu-
coneogenesis, VLDL synthesis, decrease glucose uptake 
and cause overall IR.
Visceral adipose tissue is characterized by a relatively 
higher secretion of IL-1 and PAI-1, whereas leptin and 
adiponectin secretion is greater in subcutaneous adipose 
tissue (8). This accounts for the relationship between vis-
ceral obesity and infl ammatory/thrombotic events, and 
explains the eff ectivity of TZD to improve insulin sensitiv-
ity by redistribution of lipids to subcutaneous adipose 
tissue (69).
In obese individuals there are increased plasma leptin 
concentrations and exogenous administration of leptin 
has no eff ect on body weight (8). The phenomenon has 
been explained as leptin resistance or desensitization 
(23). Besides, soluble leptin receptor concentrations are 
low in obesity and hence the fraction of bound leptin 
concentrations. This feature is independently associated 
with abdominal obesity and IR. Soluble leptin receptors 
are thought to be important for transport to or over the 
blood – brain barrier and it is the saturation of this trans-
port or impairment of leptin receptor signal transduction 
that may be the cause of leptin resistance. Leptin concen-
trations in the cerebrospinal fl uid of obese patients are 
only modestly increased (23).
The pathophysiology of obesity
Each individual has a genetically determined weight set-
point and hence body weight is tightly regulated by an 
energy homeostatic mechanism (Figure 2) (6, 66, 71). Adi-
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žu se na svo je sre diš nje re cep to re na neu ro nima hi po ta la-
mu sa i dje lu ju ta ko da sma nju ju tje les nu te ži nu. Neu ro ni 
hi po ta la mu sa iz ra ža va ju pep ti de i nji ho ve re cep to re, ko ji 
se mo gu svr sta ti kao orek si ge ni: neu ro pep tid Y, agou ti-
po ve zan pro tein (en gl. agou ti-re la ted pro tein, AgRP), hor-
mon za kon cen tri ra nje me la ni na (en gl. me la ni n-con cen tra-
ti ng hor mo ne, MCH), orek si ni A i B; ili ano rek si ge ni: me la-
no kor ti ni (tj. hor mon ko ji po ti če me la no ci te; en gl. me la no-
cyte-sti mu la ti ng hor mo ne, α-MSH) i tran skri pt po ve zan s 
ko kai nom i am fe ta mi nom (en gl. co cai ne and am phe ta mi-
ne re la ted tran scri pt, CART). U sta nju preo bi lja lep ti na ili 
in zu li na prev la da va ju ano rek si ge ni pu to vi: po ra st pot roš-
nje ener gi je, po ra st ter mo ge ne ze, sma njen unos hra ne. 
Sma nje ne se rum ske kon cen tra ci je lep ti na i in zu li na do vo-
pocytes secrete leptin and β-cells secrete insulin, both in 
proportion to the body-fat content. The two hormones 
enter the brain. They bind to their central receptors on 
the hypothalamic neurons exerting eff ects to reduce 
body weight. Hypothalamic neurons express peptides 
and their receptors that could be categorized as orexi-
genic: neuropeptide Y, agouti-related protein (AgRP), 
melanin-concentrating hormone (MCH), orexins A and B; 
or anorexigenic: melanocortins (i.e. melanocyte-stimu-
lating hormone, α-MSH) and cocaine and amphetamine 
related transcript (CART). In leptin or insulin abundance 
the anorexigenic pathways prevail: increase of energy 
expenditure, increase of thermogenesis, diminished food 
intake. Decreased leptin and insulin serum concentrations 
FIGURE 2. Energy homeostasis. NeuropeptideY (NPY)/agouti related 
protein (AgRP) neurons and proopiomelanocortin (POMC)/cocaine 
and amphetamine related transcript (CART) neurons in the arcuate 
nucleus in the hypothalamus receive signals from the periphery. They 
relay orexigenic and anorexigenic signals to the downstream neurons, 
which provide balance between the food intake and energy expendi-
ture (6,66,71).
Solid line: stimulation; dashed line: inhibition. PYY, peptide YY3-36; Y1R 
and Y2R, subtypes of neuropeptide Y receptor; a-MSH, a-melanocyte 
stimulating hormone derived by cleavage of POMC; Mc4R, melanocor-
tin 4 receptor; GHSR, growth hormone secretagogue receptor (recep-
tor for ghrelin); InsR, insulin receptor; MCH, melanin concentrating hor-
mone; TRH, thyrotropin-releasing hormone; CRH, corticotropin-releas-
ing hormone.
SLIKA 2. Energetska homeostaza. Neuroni neuropeptida Y (NPY)/pro-
teina povezanog s agouti (AgRP) te neuroni proopiomelanokortina 
(POMC)/transkripta povezanog s kokainom i amfetaminom (CART) u 
lučnoj jezgri hipotalamusa primaju signale iz periferije. Oni prenose 
oreksigene i anoreksigene signale do nizvodnih neurona koji osigu-
ravaju ravnotežu između unosa i potrošnje energije (6, 66, 71).
Puna crta: poticanje; isprekidana crta: suzbijanje. PYY, peptid YY3-36; 
Y1R i Y2R, podtipovi receptora neuropeptida Y; a-MSH, hormon za 
poticanje a-melanocita, izveden cijepanjem POMC; Mc4R, receptor 
melanokortina 4; GHSR, sekretagogni receptor hormona rasta (recep-
tor za grelin); InsR, inzulinski receptor; MCH, hormon za koncentriran-
je melanina; TRH, hormon za otpuštanje tirotropina; CRH, hormon za 
otpuštanje kortikotropina.
Mli nar B. i sur. Inzulinska rezistencija, pretilost i metabolički sindrom
Mli nar B. et al. Insulin Resistance, Obesity and Metabolic Syndrome
Biochemia Medica god. 16, br. 1, 2006.  Biochemia Medica Vol. 16, No. 1, 2006
18
de do ak ti vi ra nja orek si genih pu to va, što do vo di do nis ke 
sto pe me ta bo liz ma i po ja ča nog ape ti ta (6).
Lep tin i in zu lin pos re du ju du go roč nu re gu la ci ju tje les ne 
ma se. Oni su is to ta ko dje lat ni u krat ko roč nim sig na li ma 
ko ji ma se po je di ni ob rok za po či nje ili zav r ša va. Uz to, 
unos hra ne pra ćen je ne kim dru gim krat kod je lu ju ćim hor-
mo ni ma/čimbenicima: gre lin, mo ti lin, neu ro me din U, neu-
ro ten zin (70), ko le cis to ki nin, pep tid YY3-36 (en gl. pep ti de 
YY3-36, PYY) (71) i glu ka go nu sli čan pep ti d-1 (72), od ko jih 
se svi lu če u pro bav nom sus ta vu, te va gal nim afe ren tnim 
sig na li zi ra njem (72). Gre lin se lu či u ba zi že lu ca i po ja ča-
va os je ćaj gla di te po ti če praž nje nje že lu ca (70), dok PYY 
sig na li zi ra si to st i suz bi ja cri jev nu pok ret lji vo st (71). Gre lin 
po ti če neu ro pep tid Y i ArRP neu ro ne, dok PYY suz bi ja te 
iste neu ro ne kod ži vo ti nja (71). Ne dav no je ot kri ven pep-
tid iz ve den iz is to ga pro hor mo na kao gre lin. Naz va li su 
ga obes ta tin, a on se sup rot stav lja učin ci ma gre li na (73).
Iz gle da ka ko je lep tin sko-me la no kor tin ski put ano rek si-
ge nog sig na li zi ra nja oso bi to oču van me đu vr sta ma i mu-
ta ci je ge na ko ji ko di ra ju sas tav ni ce ovo ga pu ta, od nos no 
lep tin, lep tin ski re cep tor, pro-o pio me la no kor tin (en gl. 
pro-o pio me la no cor tin, POMC), pro hor mo n-kon ver ta zu 1 
(en gl. pro hor mo ne-con ver ta se 1, PC1) i re cep tor me la no-
kor ti na 4 (en gl. me la no cor tin 4 re cep tor, Mc4R), uz ro ku ju 
ri jet ke ob li ke bo les ne mo no ge ne pre ti los ti te do vo de do 
ne kih pri rod no nas ta lih mo de la pre ti los ti kod mi še va i šta-
ko ra (ob, db, Ay i mg) (6). Sup rot no to me, uk la nja nje ge na 
(knoc kout) za orek si ge ne pu to ve kod mi ševa ne do vo di 
do stva ra nja kr tih fe no ti po va, uka zu ju ći na iz nim no snaž-
ne uza jam ne učin ke sas tav ni ca u sus ta vu ana bo liz ma i po-
ras ta te ži ne (71).
Da naš nja vi so ka in ci den ci ja pre ti los ti mog la bi se ob jas ni-
ti hi po te zom o “šted lji vom ge no ti pu”: kroz du ža vre men-
ska raz dob lja bi ra li su se ale li ko ji po go du ju po ras tu te ži-
ne i poh ra ni mas ti ka ko bi se osi gu ra li dos tat ni nut ri jen ti 
za vri je me nedos tat ka hra ne. U da naš nje vri je me dos tup-
nos ti hra ne i sma nje nje tje les ne ak tiv nos ti tak vi ge no ti po-
vi uz ro ku ju pre ti lo st (74).
Spo sob no st ti je la da pre ciz no od r ža va tje les nu te ži nu od-
ra ža va se u neus pje hu in ter ven ci ja ko ji ma je cilj sma nje-
nje tje les ne te ži ne. Di je te og ra ni če nih ka lo ri ja do vo de do 
kom pen za cij skog po ras ta ra zi na gre li na, či me se po ti če 
uzi ma nje hra ne (71). Sma njenje tje les ne te ži ne re zul ti ra 
pa dom ra zi na lep ti na, što opet po ti če po ra st te ži ne (71). 
Ki rur ško uk la nja nje mas nog tki va do vo di do ob nav lja nja 
mas ti na no vim lo ka ci ja ma, dok po ti ca nje ter mo ge ne ze 
ad re ner gič nim β3-a go nis ti ma iza zi va kom pen za cij ski od-
go vor središ nje ga živ ča nog sus ta va (6). Tek se je kraj njom 
in ter ven ci jom u mi še va s op sež nom pre kom jer nom ek-
spre si jom ne ve zu ju ćeg pro tei na-3 (U CP-3), ko ji je sig nal-
na bje lan če vi na u ter mo ge ne zi, us pje lo prev la da ti sre diš-
nje pri la god be ne me ha niz me i mi še vi su os tali mr ša vi 
(75). Kod lju di je us pje šan ope ra cij ski zah vat že lu ča nog 
pre moš te nja, ko ji do vo di do sni že nja plaz mat ske kon cen-
lead to the activation of orexigenic pathways resulting in 
low metabolic rate and enhanced appetite (6).
Leptin and insulin mediate long-term body mass regula-
tion. They are also active in short-term signals that eff ect 
single meal to be initiated and terminated. In addition, 
there are some other short-acting hormones/factors 
which accompany food intake: ghrelin, motilin, neuro-
medin U, neurotensin (70), cholecystokinin, peptide YY3-36 
(PYY) (72) and glucagon-like peptide-1 (72), all secreted 
by the gastrointestinal tract, and vagal aff erent signaling 
(71). Ghrelin is secreted by the stomach fundus and in-
creases the sense of hunger and stimulates gastric emp-
tying (70), whereas PYY signals satiety and inhibits gut 
motility (71). Ghrelin stimulates neuropeptide Y and AgRP 
neurons, while PYY exerts inhibition of the same neurons 
in animals (71). Recently, a peptide derived from the same 
prohormone as ghrelin, was discovered. It has been named 
obestatin and it opposes the eff ects of ghrelin (73).
Particularly the leptin-melanocortin anorexigenic signal-
ing pathway appears to be very conserved among spe-
cies, and mutations in genes encoding for components of 
this pathway: leptin, leptin receptor, pro-opiomelanocor-
tin (POMC), prohormone-convertase 1 (PC1), and mela-
nocortin 4 receptor (Mc4R), cause rare forms of morbid 
monogenic obesity and lead to some naturally occurring 
murine models of obesity (ob, db, Ay and mg) (6). On the 
contrary, knockouts in genes for orexigenic pathways in 
mice fail to produce lean phenotypes, demonstrating 
the extremely powerful mutual eff ects of anabolism and 
weight gain system components (71).
Today’s high incidence of obesity could be explained by 
the “thrifty genotype” hypothesis: over periods of time 
the alleles were selected which favored weight gain and 
fat storage in order to provide enough nutrients for times 
of food deprivation. In today’s times of food availability 
and decreased physical activity such genotypes cause 
obesity (74).
The potential of the body to precisely maintain body 
weight is refl ected in the failure of interventions aimed at 
body weight reduction. Calorie-restricted diet results in 
compensatory increase in ghrelin levels thereby stimulat-
ing eating (71). Reduction of body weight results in the fall 
of leptin levels, which again stimulates weight gain (71). 
Surgical removal of adipose tissue results in restoration 
of fat at new locations, and stimulation of thermogenesis 
by adrenergic β3-agonists elicits a compensatory central 
nerve system response (6). Only extreme intervention in 
mice with gross overexpression of uncoupling protein-3 
(UCP-3), which is a signal protein in thermogenesis, was 
successful to override central adaptive mechanisms, 
and mice remained lean (75). In humans, gastric bypass 
surgery is successful as it results in ghrelin plasma con-
centration decrease and PYY increase, which suppresses 
hunger and maintains reduced body weight (71).
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tra ci je gre li na i po ras ta PYY ko ji za tom lju je glad i od r ža va 
sma nje nu tje les nu te ži nu (71).
Raz voj mr ša vog ži vo tinj skog mo de la suz bi janjem raz vo ja 
mas nog tki va re zul ti rao je hi per fa gič nim mi še vi ma s teš-
kim di ja be te som ot por nim na in zu lin (76). Pret pos tav lje ni 
me ha ni zam ko ji je uz ro ko vao IR bio je ne dos ta tak lep ti na 
i adi po nek ti na zbog od sut nos ti mas nog tki va. Nai me, da-
va nje ovih hor mo na za jed no preok re nu lo je sta nje IR (77). 
Ta ko se či ni da su ova dva hor mo na pot reb na za nor mal-
nu in zu lin sku os jet lji vo st.
Uz mo no ge ne ob li ke pre ti los ti pos to ji ba rem 20 ri jet kih 
sin dro ma s oči tom ge net skom os no vom ko ji iz gle da ju slo-
že ni ji ma, jer se po ve zu ju s ve ćim bro jem dis fun kci ja (men-
tal na re tar da ci ja, vi šes tru ki zna ci po re me ća ja hi po ta la mu-
sa) (66).
Obič na pre ti lo st u lju di smat ra se oli go ge nim sta njem i 
nje zi nu iz ra že no st mi je nja ju mno gob roj ni mo di fi  ci ra ju ći 
ge ni i čim be ni ci oko li ne: unos hra ne, tje les na aktiv no st i 
pu še nje (6). Proc je nju je se ka ko ge net ska os no va sud je lu-
je s 40–80% u pa to fi  zio lo gi ji pre ti los ti (66). Iden ti fi  ci ra na 
su naj ma nje 204 na vod na gen ska lo ku sa ud ru že na s pre ti-
loš ću, a oni ko ji su pot vr đe ni u vi še stu di ja pri ka za ni su u 
tab li ci 1. (78).
Me ta bo lički sin drom
Gru pi ra nje hi per ten zi je, hi per gli ke mi je i gih ta pr vo bit no 
je pre poz na to još dva de se tih go di na 20. sto lje ća (1). Rea-
ven je 1988. go di ne iden ti fi  ci rao sin drom X ko ji pot je če iz 
IR. Go di ne 2004. je III. pa nel o li je če nju od ras lih Nacio nal-
nog ob ra zov nog prog ra ma o ko les te ro lu (en gl. Natio nal 
Cho les te rol Edu ca tion Prog ra m’s Adu lt Treat me nt Pa nel III, 
ATPIII) de fi  ni rao me ta bo lič ki sin drom pod al ter na tiv nim 
Development of lean animal model by suppression of ad-
ipose tissue development resulted in hyperphagic mice 
with severe insulin resistant diabetes (76). The hypoth-
esized mechanism causing IR was leptin and adiponectin 
defi ciency due to the absence of adipose tissue. Namely, 
the administration of these hormones together reversed 
IR (77). Thus, these two hormones appear to be required 
for normal insulin sensitivity.
Besides monogenic forms of obesity there are at least 
20 rare syndromes with obvious genetic basis, which 
appears to be more complex as it predisposes more dys-
functions (mental retardation, multiple signs of hypotha-
lamic disorder) (66).
The common human obesity is thought to be an oligo-
genic state and its expression is modulated by multiple 
modifi er genes and by environmental factors: food intake, 
physical activity, and smoking (6). The genetic basis in the 
pathophysiology of obesity is estimated to be 40%-80% 
(66). At least 204 putative gene loci associated with obesity 
have been identifi ed, and those which have been con-
fi rmed by multiple studies are presented in Table 1 (78).
Metabolic Syndrome
The fi rst recognition of clustering of hypertension, hyper-
glycemia and gout came already in the twenties of 20th 
century (1). In 1988, Reaven identifi ed syndrome X origi-
nating from IR. In 2004, the National Cholesterol Educa-
tion Program’s Adult Treatment Panel III (ATPIII) defi ned 
the metabolic syndrome with alternative names: IR syn-
drome, Reaven syndrome, characterized by the following 
components (G52):
Ge ne na me* Protein na me Ge ne na me* Protein na me
ADIPOQ Adi po nec tin LEPR Lep tin re cep tor
ADRA2A Ad re ner gic re cep tor α-2A NR3C1 Nuclear re cep tor sub fa mi ly 3, group C
ADRA2B Ad re ner gic re cep tor α-2B PPARG PPA R-γ
ADRB1 Ad re ner gic re cep tor β-1 UCP1 Uncoup li ng pro tein 1
ADRB2 Adre ner gic re cep tor β-2 UCP2 Un coup li ng pro tein 2
ADRB3 Ad re ner gic re cep tor β-3 UCP3 Un coup li ng pro tein 3
DRD2 Dopa mi ne re cep tor D2 TNF TNF-α 
LEP Lep tin LIPE Hor mo ne sen si ti ve li pa se
* according to HUGO No men cla tu re Com mit tee
TABLE 1. The li st of ge nes as so cia ted wi th obe si ty con fi r med by 
5 or mo re stu dies
TAB LI CA 1. Po pis ge na ud ru že nih s pre ti loš ću pot vr đe nih u 5 ili 
vi še stu di ja
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ime ni ma: sin drom IR i Rea ve nov sin drom, obi lje žen sli je-
de ćim sas tav ni ca ma (G52):
ab do mi nal na pre ti lo st
ate ro ge na dis li pi de mi ja
hi per ten zi ja
IR
prou pal no sta nje
prot rom bot sko sta nje
Ova kli nič ka obi ljež ja su snaž ni čim be ni ci ri zi ka za šećer-
nu bolest tipa 2 i kar dio vas ku lar nu bo le st s mo gu ćim do-
dat nim kom pli ka ci ja ma uk lju ču ju ći ko les te rol ne žuč ne 
ka men ce, ap ne ju u snu, sin drom po li cis tič nog jaj ni ka kod 
že na, mas nu jet ru i ne ke vr ste ra ka (7).
Pret pos tav lje ne su tri mo gu će etio lo gi je za me ta bo lički 
sin drom: ut vr đe no je ka ko je pre ti lo st od go vor na za pre-
kom jer no ot puš ta nje slo bod nih mas nih ki se li na, ci to ki na 
i dru gih prou pal nih proiz vo da ko ji su up le te ni u raz voj 
IR, hi per ten zi je i dis li pi de mi je. IR kao dru gi mo gu ći uz rok 
me ta bo lič kog sin dro ma pos tav lja pi ta nje je li mo gu će raz-
dvo ji ti pre ti lo st i IR. Zap ra vo, IR u raz li či tim stup nje vi ma 
pos to ji u svim ka te go ri ja ma in dek sa tje les ne ma se, uka zu-
ju ći na njen neo vi san nas ljed ni dop ri nos, ba rem do ne ke 
mje re. Ne ke po pu la ci je (iz juž ne Azi je) s bla go pre kom jer-
nom tje les nom te ži nom po ka zu ju IR i to se smat ra pri mar-
nom IR. S tog sta ja liš ta se IR mo že svr sta ti kao za se ban 
etio loš ki čim be nik za me ta bo lič ki sin drom. Hi pe rin zu li ne-
mi ja kao pos lje di ca IR mo že po ve ća ti lu če nje VLDL iz jet re 
i uz ro ko va ti hi per ten zi ju. Mi šić na IR mo že uz ro ko va ti hi-
per gli ke mi ju ko ja se po ja ča va glu ko neo ge ne zom kod jet-
re re zis ten tne na in zu lin (7). Smat ra se da tre ća etio lo gi ja 
uk lju ču je neo vis ne čim be ni ke: imune, vas ku lar ne, jet re ne 
itd., na ko je ut je če spe ci fi č na ge net ska os no va po je di ne 
oso be, kao i čim be ni ci oko li ne (7).
Kli nič ke po jav nos ti i kri te ri ji za di jag nos ti ci ra nje me-
ta bo lič kog sin droma
Ra zi ne glu ko ze i FFA u plaz mi
Hi pe rin zu li ne mi ja se raz vi ja kao pos lje di ca IR. U ovom sta-
nju su kon cen tra ci je FFA u plaz mi tek um je re no po vi še ne, 
dok kon cen tra ci ja glu ko ze mo že bi ti nor mal na ili po vi še-
na. Ova po to nja uka zu je na po re me će nu to le ran ci ju glu-
ko ze, ko ja se do ka zu je vri jed nos ti ma oral no ga tes ta to le-
ran ci je glu ko ze (OGTT) vi šim od nor mal nih, ali još uvi jek 
ne to li ko po vi še nim da bi oz na ča va le šećernu bolest (79). 
Dru go mo gu će obi ljež je me ta bo lič kog sin dro ma je po re-
me će na glu ko za na taš te (7). Kad se kon cen tracije in zu lin u 
plaz mi sni ze kao re zul tat raz grad nje β-sta ni ca, ra zi ne FFA 
se znat no po vi su ju uz pop rat nu hi per gli ke mi ju i sta nje me-
ta bo lič kog sin dro ma pre ras ta u šećernu bolest (79).
Ate ro ge na dis li pi de mi ja
Hi per trig li ce ri de mi ja nas ta je kao pos lje di ca po ve ća ne sin-













These clinical features are strong risk factors for DM2 and 
cardiovascular disease with additional possible complica-
tions including cholesterol gallstones, sleep apnea, poly-
cystic ovary syndrome in women, fatty liver and some 
types of cancer (7).
Three possible etiologies for the metabolic syndrome 
have been postulated: obesity was found to be respon-
sible for excess release of FFA, cytokines and other proin-
fl ammatory products which are implicated in the devel-
opment of IR, hypertension and dyslipidemia.
IR as the second possible cause of metabolic syndrome 
rises a question of whether it is possible to dissociate be-
tween obesity and IR. Indeed, IR exists to various degrees 
in all particular classes of body mass index, suggesting 
an independent inheritable contribution of it to at least 
some extent. Some populations (South Asians) with mild 
overweight display IR and this is said to be primary IR. 
From this point of view IR can be classifi ed as a separate 
etiological factor for metabolic syndrome. Hyperinsu-
linemia as a consequence of IR is capable to increase 
VLDL secretion from the liver and to cause hypertension. 
IR of muscle can cause hyperglycemia, exaggerated by 
gluconeogenesis in insulin-resistant liver (7).
The third etiology is thought to include independent fac-
tors: immune, vascular, hepatic, etc., which are infl uenced 
by specifi c genetic background of an individual, and by 
environmental factors (7).
Clinical manifestations and criteria for the diagnosis 
of metabolic syndrome
Glucose and FFA plasma level
As a consequence of IR, hyperinsulinemia develops. In 
this condition plasma FFA concentrations are only mod-
erately elevated, but glucose concentration can be nor-
mal or increased, the latter denoting impaired glucose 
tolerance which is demonstrated by oral glucose toler-
ance test (OGTT) values above normal, yet not elevated 
enough to defi ne DM (79). Another possible feature in 
the metabolic syndrome is impaired fasting glucose (7). 
When plasma insulin concentrations decline, as a result 
of β-cell degeneration, FFA levels increase considerably 
with accompanying hyperglycemia and the condition of 
metabolic syndrome grows to DM2 (79).
Atherogenic dyslipidemia
As a consequence of increased liver VLDL synthesis hy-
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lje no st ma log gus tog HDL. Slič no to me, sas tav LDL se po-
mi če pre ma prev las ti ma log gus tog LDL. Ovaj po to nji se 
smat ra ate ro ge ni jim od obič nog LDL. Is to ta ko do la zi do 
prom je na u apo li pop ro tei ni ma (1).
Hi per ten zi ja
Kod zdra vih oso ba in zu lin po ti če sim pa tič ki živ ča ni sus tav 
i dje lu je na kr vne ži le uz ro ku ju ći va zo di la ta ci ju. In zu lin is-
to ta ko po ti če po nov nu ap sor pci ju nat ri ja u bub re gu. U 
sta nju in zu lin ske re zis ten ci je va zo di la ta ci ja se mo že iz gu-
bi ti, ali se uči nak na bub re ge i sim pa tič ka sti mu la ci ja od-
r ža va ju i čak po ve ća va ju. To obo je dop ri no si hi per ten zi ji, 
ko ji do dat no po gor ša va ju FFA ko je po go du ju va zo kon-
strik ci ji. Pa ipak, či ni se ka ko do ga đa ji po ve za ni iz rav no 
s IR ima ju tek um je re nu ulo gu u raz vo ju hi per ten zi je (1). 
Uz to, lep tin bi mo gao u sta no vi toj mje ri dop ri no si ti hi per-
ten zi ji, jer plaz mat ske kon cen tra ci je lep ti na ve za nog uz 
bje lan če vi ne kod nor mo ten ziv nih muš ka ra ca ko re li ra ju 
sa sim pa tič kom živ ča nom ak tiv noš ću (26).
Os ta la kli nič ka obi ljež ja
Prou pal no sta nje je obi lje že no po ras tom C-reak tiv nog 
pro tei na u plaz mi, a prot rom bot sko sta nje po vi še njem 
PAI-1 i fi b ri no ge na (7).
Do dat ne po jav nos ti me ta bo lič kog sin dro ma su: mas na 
jet ra i stea to he pa ti tis zbog po ve ća ne jet re ne proiz vod nje 
VLDL u sta nju IR, hi pe ru ri ce mi ja, po vi še ni ho mo cis tein i 
vas ku lar ne ne nor mal nos ti s mik roal bu mi nu ri jom (1). Oso-
bi to je za nim lji va hi pe ru ri ce mi ja, ko ja je naj vje ro jat ni je 
pos lje di ca hi pe rin zu li ne mi je: bub reg ko ji od r ža va nor mal-
nu os jet lji vo st za in zu lin pri la go đa va se na vi so ke kon cen-
tra ci je in zu li na sma nje nim lu če njem mok rać ne ki se li ne, 
či me se po ve ća va nje go va ra zi na u plaz mi (79).
Dru gi va žan kli nič ki bi ljeg IR je cr nkas ta akan to za (2) ko-
ja se oči tu je kao hi per pig men ti ra ne kož ne prom je ne zas-
no va ne na epi der mnoj hi per pla zi ji. Smat ra se ka ko je ovo 
obi ljež je po ve za no s hi pe rin zu li ne mič nim sta njem, jer se 
je po ka za lo da in zu lin ub r za va ra st epi der mnih sta ni ca u 
kul tu ri (80).
Di jag nos tič ki kri te ri ji što su ih prih va ti li ATPIII i In ter na tio-
nal Dia be tes Fe de ra tion (en gl. In ter na tio nal Dia be tes Fe de-
ra tion, IDF) pri ka za ni su u tab li ci 2. Pre ma do go vo ru pri 
ATPIII, di jag no za me ta bo lič kog sin dro ma mo že se pos ta-
vi ti u bo les ni ka ko ji ima ju naj ma nje 3 od 5 sli je de ćih obi-
ljež ja: ab do mi nal nu pre ti lo st, po vi še ne trig li ce ri de, sni žen 
HDL-koles te rol, po vi šen kr vni tlak ili po vi še nu glu ko zu u 
plaz mi na taš te (7). Kri te ri ji ko je je pos ta vio IDF ug lav nom 
su suk lad ni oni ma iz ATPIII (81). Ma nje raz li ke od no se se 
na sre diš nju pre ti lo st kao glav no obi ljež je i is pu nja va nje 
dvi ju od če ti ri dru ga po jav nos ti. Gra nič na kon cen tra ci ja 
glu ko ze ni ža je u kri te ri ji ma IDF, pri čem se pre po ru ča nap-
ra vi ti OGTT kad je vri jed no st vi ša.
a greater proportion of small dense HDL. Similarly, the 
composition of LDL is shifted towards predominance of 
small dense LDL. The latter is thought to be more athero-
genic than ordinary LDL. Changes of apolipoproteins also 
occur (1).
Hypertension
In healthy subjects insulin stimulates sympathetic ner-
vous system and acts on blood vessels causing vasodila-
tation. Insulin also stimulates sodium reabsorption in the 
kidney. In insulin resistant state the vasodilatation can be 
lost but the renal eff ect and sympathetic stimulation are 
maintained and even increased. Both contribute to hy-
pertension, which is further exacerbated by FFA favoring 
vasoconstriction. Nevertheless, it appears that the events 
linked directly to IR play only a moderate role in the de-
velopment of hypertension (1). Additionally, leptin might 
have some contribution to hypertension as protein-
bound leptin plasma concentrations in normotensive 
men correlate with sympathetic nerve activity (26).
Other clinical features
Proinfl ammatory state is characterized by a rise in plasma 
C-reactive protein, and prothrombotic state by elevation 
of PAI-1 and fi brinogen (7). Additional manifestations of 
the metabolic syndrome are fatty liver and steatohepa-
titis because of increased liver VLDL production in the 
state of IR, hyperuricemia, increased homocystein, and 
vascular abnormalities with microalbuminuria (1). Par-
ticularly interesting is hyperuricemia which is most likely 
a consequence of hyperinsulinemia: the kidney which 
maintains normal sensitivity to insulin, adapts to high 
insulin concentrations by decreased uric acid secretion, 
thereby elevating its plasma level (79).
Another important clinical marker of IR is acanthosis 
nigricans (2), which manifests as hyperpigmented skin 
changes based on epidermal hyperplasia. The feature is 
thought to be related to the hyperinsulinemic state, as 
insulin was shown to accelerate epidermal cell growth in 
culture (80).
Diagnostic criteria accepted by ATPIII and International 
Diabetes Federation (IDF) are presented in Table 2. Ac-
cording to ATPIII agreement, patients having at least 3 of 
5 characteristics can be diagnosed as having the meta-
bolic syndrome: abdominal obesity, elevated triglycer-
ides, decreased HDL-cholesterol, increased blood pres-
sure or increased fasting plasma glucose (7). IDF declares 
criteria fairly consistent with ATPIII (82). Slight diff erences 
include central obesity as the major feature and fulfi lled 
two of four other manifestations. The borderline glucose 
concentration is lower in IDP criteria, with a strong rec-
ommendation for OGTT when exceeded.
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Zak lju čak
Glav ni os nov ni uz rok IR je vis ce ral na pre ti lo st, jer je vis ce-
ral no mas no tki vo sklo ni je li po li zi od pot kož nog mas nog 
tki va. Smat ra se ka ko su naj važ ni ji me ha niz mi za raz voj IR 
po ve ća no lu če nje FFA, sni že ne kon cen tra ci je adi po nek ti-
na, lep ti na, IL-6 i dru gih adi po ki na. Uz to što je IR pri sut-
na za jed no s pre ti loš ću i dru gim obi ljež ji ma poz na tim kao 
me ta bo lič ki sin drom, smat ra se da ima važ nu ulo gu i u 
raz vo ju sin dro ma po li cis tič nih jaj ni ka kod že na (82) te da 
je glav no obi ljež je kod li po dis tro fi  ja (83). Ove po to nje su 
obi lje že ne se lek tiv nim gu bit kom mas nog tki va, što uka zu-
je na to da je od re đe na ko li či na mas nog tki va neop hod na 
za nor mal nu in zu lin sku os jet lji vo st, vje ro jat no ta ko što osi-
gu ra va mjes to za poh ra nu trig li ce ri da, te što lu či do volj no 
adi po nek ti na i lep ti na (77).
Me đu tim, tek va lja u pot pu nos ti raz jas ni ti etio lo gi ju bo les-
ti ud ru že nih s IR. Pos to je pri go vo ri de fi  ni ra nju pre ti los ti 
i s njom po ve za nih kar dio vas ku lar nih ri zič nih čim be ni ka 
kao “me ta bo lič ki sin drom” zbog ne si gur nos ti nji ho va za-
jed nič kog pod ri jet la (84). S dru ge pak stra ne, po jav lju ju 
se no va važ na saz na nja o no voot kri ve nom in zu li n-mi me-
tič nom adi po ki nu pod ri jet lom iz mas nog tki va. Naz van je 
vis fa tin, jer je u znat no ve ćim kon cen tra ci ja ma ot kri ven u 
vis ce ral nom ne go u pot kož nom mas nom tki vu. Za vis fa-
tin je po ka za no ka ko sni ža va kon cen tra ci ju glu ko ze u plaz-
mi i dje lu je neo vis no od in zu li na, vje ro jat no ve žu ći se za 
raz li či ta vez na mjes ta is to ga re cep to ra (85).
Bo lje ra zu mi je va nje me ha ni za ma ko ji do vo de do IR i ud-
ru že nih bo les ti te ot kri va nje do dat nih te ra pij skih ci lje va 
kao što je vis fa tin bi ti će ko ris no u li je če nju na joz bilj ni jih 
kom pli ka ci ja IR – šećerne bolesti tipa 2 i kar dio vas kular ne 
bo les ti.
Conclusion
The main underlying cause of IR is visceral obesity, as vis-
ceral adipose tissue is more prone to lipolysis than subcu-
taneous adipose tissue. The most important mechanisms 
for the development of IR are thought to be increased se-
cretion of FFA, and decreased adiponectin, leptin, IL-6 and 
other adipokine concentrations. Besides the coexistence 
of IR with obesity and other features known as metabolic 
syndrome, IR is thought to play an important role in the 
development of polycystic ovary syndrome in women 
(82) and is the main feature of lipodystrophies (83). The 
latter are characterized by selective loss of adipose tissue, 
which indicates that a certain amount of adipose tissue 
is necessary for normal insulin sensitivity, presumably by 
providing the place for triglyceride storage and by secret-
ing suffi  cient adiponectin and leptin (77).
However, the etiology of IR-associated disorders remains 
to be fully elucidated. There are some objections to de-
fi ning obesity and related cardiovascular risk factors as 
the metabolic “syndrome” for the uncertainty about their 
common origin (84). On the other hand, some important 
knowledge is arising such as about a newly discovered 
insulin-mimetic adipokine derived from adipose tissue. 
It has been named visfatin for being detected in a much 
higher concentration in visceral than in subcutaneous 
adipose tissue. It has been shown to lower plasma glu-
cose concentration and to act independently of insulin, 
presumably by binding to a diff erent binding site of the 
same receptor (85).
Better understanding of the mechanisms leading to IR 
and associated diseases, and discovery of additional 
therapy targets such as visfatin would prove benefi cial in 
the management of the most serious complications of IR, 
DM2 and cardiovascular disease.
ATPIII IDF
Clinical fea tu re De fi  ni ng le vel De fi  ni ng le vel
Central obe si ty –
wai st cir cum fe ren ce
men >102 cm men (Eu ro pean) ≥94 cm (or spe ci fi c va lues for ot her et hnic grou ps)
women >88 cm women (European) ≥80 cm
Plus any 2 of the fol lowi ng:
Trig lyce ri des ≥1.7 mmol/L ≥1.7 mmol/L or spe ci fi c treat me nt
HDL-cho les te rol
men ≤1.03 mmol/L men ≤1.03 mmol/L or spe ci fi c treat me nt
women ≤1.29 mmol/L women ≤1.29 mmol/L
Blood pres su re ≥130/≥85mm Hg
≥130/≥85 mm Hg or treatment of pre-
vious ly diag no sed hyper ten sion
Fas ti ng plas ma glu co se ≥6.1 mmol/L ≥5.6 mmol/L or pre vious ly diag no-sed DM2
TABLE 2. Diag nos tic cri te ria for me ta bo lic syndro me ac cor di ng 
to ATPIII (7) and IDF (81)
TAB LI CA 2. Di jag nos tič ki kri te ri ji za me ta bo lički sin drom pre ma 
ATPIII (7) i IDF (81)
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